CDK4/6-IN-15

• CAT Number: I042323
• CAS Number: 2078047-99-9
• Molecular Formula: C21H27FN8S
• Molecular Weight: 442.56
• Purity: ≥95%
• Synonyms: 5-[2-[[5-[4-(dimethylamino)piperidin-1-yl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-N,4-dimethyl-1,3-thiazol-2-amine
• InChI: InChI=1S/C21H27FN8S/c1-13-19(31-21(23-2)26-13)18-16(22)12-25-20(28-18)27-17-6-5-15(11-24-17)30-9-7-14(8-10-30)29(3)4/h5-6,11-12,14H,7-10H2,1-4H3,(H,23,26)(H,24,25,27,28)
• InChIKey: NAGFLZVMWVHHLW-UHFFFAOYSA-N
• SMILES: CC1=C(SC(=N1)NC)C2=NC(=NC=C2F)NC3=NC=C(C=C3)N4CCC(CC4)N(C)C

CDK4/6-IN-15（Cat No.:I042323）is a small molecule inhibitor that targets cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial for cell cycle progression, particularly in the transition from the G1 phase to the S phase. By inhibiting these kinases, CDK4/6-IN-15 disrupts cell division, thereby slowing down the proliferation of cancer cells, especially in tumors that rely on these pathways for growth. It has shown potential in preclinical studies for treating cancers like breast cancer. Ongoing research is focused on evaluating its safety, efficacy, and potential for clinical use in cancer therapy.